Wireless transcutaneous electrical nerve stimulation device for chemotherapy-induced peripheral neuropathy: an open-label feasibility study

Jennifer S Gewandter; Jenna Chaudari; Chinazom Ibegbu; Rachel Kitt; Jennifer Serventi; Joy Burke; Eva Culakova; Noah Kolb; Kathleen A Sluka; Mohamedtaki A Tejani; Nimish A Mohile

doi:10.1007/s00520-018-4424-6

Back

Wireless transcutaneous electrical nerve stimulation device for chemotherapy-induced peripheral neuropathy: an open-label feasibility study

Journal article

Open access

Peer reviewed

Wireless transcutaneous electrical nerve stimulation device for chemotherapy-induced peripheral neuropathy: an open-label feasibility study

Jennifer S Gewandter, Jenna Chaudari, Chinazom Ibegbu, Rachel Kitt, Jennifer Serventi, Joy Burke, Eva Culakova, Noah Kolb, Kathleen A Sluka, Mohamedtaki A Tejani, …

Supportive care in cancer, Vol.27(5), pp.1765-1774

05/2019

DOI: 10.1007/s00520-018-4424-6

PMCID: PMC6393221

PMID: 30151681

Files and links (1)

url

https://www.ncbi.nlm.nih.gov/pmc/articles/6393221View

Open Access

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) occurs in approximately 68% of patients who receive neurotoxic chemotherapy and lasts at least 6 months post-chemotherapy in approximately 30% of individuals. CIPN is associated with decreased quality of life and functional impairments. Evidence suggests that CIPN symptoms are caused, in part, by enhanced excitability and impaired inhibition in the central nervous system. Transcutaneous electrical nerve stimulation (TENS) decreases pain by counteracting both of these mechanisms and is efficacious in other conditions associated with neuropathic pain. This single-arm study (n = 29) assessed the feasibility of investigating TENS for CIPN after chemotherapy completion using a wireless, home-based TENS device. Eighty-one percent of eligible patients who were approached enrolled, and 85% of participants who received the TENS device completed the primary (6-week) study term. Qualitative interview data suggest that use of the device on the continuous setting that automatically alternates between 1-h stimulation and rest periods for 5 h/day would be acceptable to most participants. Significant (i.e., p < 0.05) improvements were observed with the EORTC-CIPN20 (percent change from baseline: 13%), SF-MPQ-2 (52%), numeric rating scale of pain (38%), tingling (30%), numbness (20%), and cramping (53%), and UENS large fiber sensation subscore (48%). Preliminary data that support the reliability and construct validity of the UENS for CIPN in cancer survivors are also provided. Together these data suggest that it is feasible to evaluate TENS for CIPN using a wireless, home-based device and that further evaluation of TENS for CIPN in a randomized clinical trial is warranted.

Feasibility Studies

Quality of Life

Peripheral Nervous System Diseases - chemically induced

Reproducibility of Results

Humans

Middle Aged

Peripheral Nervous System Diseases - therapy

Male

Neoplasms - drug therapy

Neurotoxicity Syndromes - etiology

Neurotoxicity Syndromes - therapy

Antineoplastic Agents - adverse effects

Female

Transcutaneous Electric Nerve Stimulation - methods

Details

Title: Subtitle: Wireless transcutaneous electrical nerve stimulation device for chemotherapy-induced peripheral neuropathy: an open-label feasibility study
Creators: Jennifer S Gewandter - Department of Anesthesiology and Perioperative Medicine, University of Rochester, Rochester, NY, USA. jennifer_gewandter@urmc.rochester.edu
Jenna Chaudari - Department of Anesthesiology and Perioperative Medicine, University of Rochester, Rochester, NY, USA
Chinazom Ibegbu - Department of Neurology, University of Rochester, Rochester, NY, USA
Rachel Kitt - Department of Anesthesiology and Perioperative Medicine, University of Rochester, Rochester, NY, USA
Jennifer Serventi - Department of Neurology, University of Rochester, Rochester, NY, USA
Joy Burke - Department of Neurology, University of Rochester, Rochester, NY, USA
Eva Culakova - Department of Surgery, University of Rochester, Rochester, NY, USA
Noah Kolb - Department of Neurology, University of Vermont Medical Center, Burlington, VT, USA
Kathleen A Sluka - Department of Physical Therapy, University of Iowa, Iowa City, IA, USA
Mohamedtaki A Tejani - Department of Medicine, Hematology/Oncology, University of Rochester, Rochester, NY, USA
Nimish A Mohile - Department of Neurology, University of Rochester, Rochester, NY, USA
Resource Type: Journal article
Publication Details: Supportive care in cancer, Vol.27(5), pp.1765-1774
DOI: 10.1007/s00520-018-4424-6
PMID: 30151681
PMCID: PMC6393221
NLM abbreviation: Support Care Cancer
ISSN: 0941-4355
eISSN: 1433-7339
Publisher: Germany
Grant note: U10 CA037420 / NCI NIH HHS UL1 TR002001 / NCATS NIH HHS UG1 CA189961 / NCI NIH HHS
Language: English
Date published: 05/2019
Academic Unit: Iowa Neuroscience Institute; Nursing; Physical Therapy and Rehabilitation Science; Neuroscience and Pharmacology
Record Identifier: 9984040282502771

Metrics

20 Record Views

25 Times Cited - Web of Science